tradingkey.logo

Zai Lab Ltd

ZLAB
View Detailed Chart
18.000USD
+1.020+6.01%
Close 02/06, 16:00ETQuotes delayed by 15 min
1.99BMarket Cap
LossP/E TTM

Zai Lab Ltd

18.000
+1.020+6.01%
Intraday
1m
30m
1h
D
W
M
D

Today

+6.01%

5 Days

+8.43%

1 Month

-1.10%

6 Months

-53.51%

Year to Date

+2.04%

1 Year

-35.28%

View Detailed Chart

TradingKey Stock Score of Zai Lab Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Zai Lab Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 41.62.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zai Lab Ltd's Score

Industry at a Glance

Industry Ranking
65 / 159
Overall Ranking
179 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Zai Lab Ltd Highlights

StrengthsRisks
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 85.54% year-on-year.
Fairly Valued
The company’s latest PE is -9.24, at a medium 3-year percentile range.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 50.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
41.625
Target Price
+145.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Zai Lab Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Zai Lab Ltd Info

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Ticker SymbolZLAB
CompanyZai Lab Ltd
CEODu (Ying)
Websitehttps://www.zailaboratory.com/
KeyAI